Cataract

Latest News


CME Content


Although cataract surgery is already the most-used intervention for glaucoma, a growing number of glaucoma specialists want to see timely glaucoma surgery accepted and reimbursed as an appropriate intervention for the long-term management of glaucoma, said Kuldev Singh, MD, MPH, professor and chief of the Glaucoma Service at Stanford University, Stanford, CA.

New data suggest that it may be time to stop worrying about broad inclusion criteria when evaluating patients with cataracts for potential femtosecond laser surgery. A retrospective review of more than 800 consecutive cases found that the technology provides high precision in the treatment of challenging cases with broad inclusion criteria, said H. Burkhard Dick, MD.

Physicians who wonder if they should make the investment in a new model of surgical system they currently use and like, the answer could be yes. Data presented by Barry Schechter, MD, showed a 22% time savings in uncomplicated cataract procedures with new equipment.

Whether a surgeon uses a laser for cataract surgery or manual methods may not make much of a difference in terms of postoperative inflammation. That at least is the experience of H. Burkhard Dick, MD, professor and chairman of ophthalmology and director of the University Eye Clinic Bochum, Bochum, Germany.

New clinical data suggest that an improved intraoperative aberrometer can help improve clinical outcomes for patients who receive an aspheric, hydrophobic IOL, said Dee Stephenson, MD, of Stephenson Eye Associates in Venice, FL.

Ophthalmology has a history of “strange,” and actually that may be good for the specialty. Of all the specialties of medicine, ophthalmology keeps seeing innovation evolve on a regular basis. The technology in this market is always evolving and it keeps getting better and more efficient.

Bausch + Lomb and CROMA have donated 50,000 units of bromfenac sodium sesquihydrate (Yellox) to projects in Africa sponsored by Light for the World.

Alcon launches new NSAID

Alcon has announced the launch of nepafenac ophthalmic suspension 0.3% (Ilevro), a new once-daily treatment option for pain and inflammation associated with cataract surgery.